All GLG News Analyses Filed Under: Ophthalmology
Analyses are solely the work of the authors and have not been edited or endorsed by GLG.
-
CATT Trial will Likely sink Genetech's (DNA) Lucentis for AMD Treatment.
February 28, 2008
Comparison of AMD Treatments Trials (CATT): Lucentis — Avastin Trial | www.pipelinereview.com
The CATT Trial will prospectively compare lucentis and avastin head to head in the management of Age Related Macular Degeneration. Lucentis costs 40X more than Avastin for ocular dosing; and many suspect that they both are similiar in efficacy. If CATT confirms this, it sink Lucentis Sales and Genetech's Proft.
-
Pediatric Contact Lens Patients
February 28, 2008
Contact lenses: A winning option for you and young patients | ecp.acuvue.com
Contacts can successfully be worn with pediatric patinets as early as 10 years of age. With that being said, patient selection is crucial. You may encounter 10 year old patients that are as responsible as 7 year olds and vice versa.
-
BVT28949. A Possible Adjunct To Prostaglandin Analogs.
February 28, 2008
Biovitrum has Completed an Exploratory Clinical Phase II Study in Glaucoma | www.pipelinereview.com
Biovitrum may have discovered a new adjunct to our existing prostaglandin analogs. Currently, the prostaglandins generally lower patients pressures by 30-40% therefore making them first line therapy. If this new 5-HT2A drug can lower pressure an additional 10%, this drug would find a home in the glaucoma world.
-
New promising agent for glaucoma treatment
February 19, 2008
Biovitrum has Completed an Exploratory Clinical Phase II Study in Glaucoma | www.pipelinereview.com
1. Glaucoma therapy 2. IOP reduction 3. Combined therapy
-
New promising glaucoma agent for glaucoma treatment
February 18, 2008
Biovitrum has Completed an Exploratory Clinical Phase II Study in Glaucoma | www.pipelinereview.com
1. glaucoma treatment 2. combined therapy 3. IOP reduction
-
Darcy RyanOptometristHertzog Eye Associates
At What Age Should Contact Lenses Be Considered for Children?
February 13, 2008
Contact lenses: A winning option for you and young patients | ecp.acuvue.com
A recent study showed that children aged 8-12 were just as successful as teenagers aged 13-17 in the areas of physiological adjustment and contact lens care. I find this is true in my practice as well. Not only can prescribing to this younger demographic change a child's life, it can also increase an Eye Care Practitioner's bottom line.
-
Steve RubinsteinOptometristSound Shore Vision Care
Bausch moving forward after takeover by Warburg Pincus
January 29, 2008
Bausch & Lomb announces acquisition of eyeonics | www.osnsupersite.com
The recent purchase by Bausch & Lomb of Eyeonics shows a good move to capture the growing presbyopic correction market. The company has also sent Ronald L. Zarrella to become chairman emeritus. One of the best moves I have heard since the whole Renu problem.
-
Barry SchechterDirector of Corneal and External DiseasesFLORIDA EYE MICROSURGICAL INSTITUTE INC
Bausch makes foray into presbyopic arena
January 29, 2008
Bausch & Lomb announces acquisition of eyeonics | www.osnsupersite.com
With the recent trends of presbyopic correction , Bausch and Lomb has now entered the arena.
-
January 28, 2008
Bausch & Lomb announces acquisition of eyeonics | www.osnsupersite.com
I HAVE BEEN PRODICTING THAT A MAJOR PLAYER WOULD BUY EYEONICS SINCE I FIRST STARTED PLACING THE CRYSTALENS IN MY PATIENTS. THE LENS WORKS BUT NEEDED A PRO AT MARKETING. B& L WILL BENIFIT FROM THIS BUY.
-
Benefits of TELESCOPIC lens implants important for those already effected by macular degeneration
January 23, 2008
Telescopic IOL device shows potential for improving quality of life in AMD patients | www.osnsupersite.com
As ophthalmologists, we have been waiting for development of a useful telescopic intraocular lens implant for over 17 years. These lenses have been in FDA trials for years, but never brought to market because of numerous problems with them. A viable telescopic lens implant would give us something to offer to patients whose maculars are already damaged by AMD to the point where they have poor central vision. Recent advances in AMD treatment, specifically Verteporforin and ant-VEGF agents, are offering patients with new onset wet AMD the prospect of slowing or even reversing the progression of this vision threatening disorder. However, there is little at this time we can do for people who already have damage to their maculae.
- Subscribe to Updates
-
Leading institutions connect with members of the Healthcare councils through GLG
Get Intelligently Connected
with the world's leading experts
GLG's 850+ Clients Include:
- More than 70% of the world's leading
- mutual funds
- 15 of the leading 20
- global banks
- 7 of the leading 10
- global private equity firms
- 5 of the leading 10
- AmLaw firms
- Fortune 500® Companies
- in nearly every industry sector, including pharmaceuticals, insurance, chemicals, energy and computer software
Most Popular Ophthalmology News
-
Ozurdex (Allergan) Uses Billing Structure That May Prevent Acceptance
November 9, 2009
-
Lumigan X EU Committee Recomendation
October 27, 2009
-
NO BRAINER: Genentech Prefers to Promote Lucentis over Avastin for Wet ARMD
October 7, 2009
-
Contact Lens Nirvana: Hyperpermeable One Day
October 2, 2009
-
Tecnis Multifocal Outperforms Competitors
September 20, 2009